Skip to main content
SpringerLink
Log in

Newer Formulations of Risperidone: Remarks About Risperidone ISM®

  • Letter to the Editor
  • Published:
CNS Drugs Aims and scope Submit manuscript

The Original Article was published on 27 May 2020

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Clark I, Taylor D. Newer formulations of risperidone: role in the management of psychotic disorders. CNS Drugs. 2020;34:841–52.

    Article  CAS  Google Scholar 

  2. Yapar E, İnal Ö, Özkan Y, Baykara T. Injectable in situ forming microparticles: a novel drug delivery system. Trop J Pharm Res. 2012;11(2):307–18.

    Article  CAS  Google Scholar 

  3. Rungseevijitprapa W, Bodmeier R. Injectability of biodegradable in situ forming microparticle systems (ISM). Eur J Pharm Sci. 2009;36(4–5):524–31.

    Article  CAS  Google Scholar 

  4. Kranz H, Bodmeier R. Structure formation and characterization of injectable drug loaded biodegradable devices: in situ implants versus in situ microparticles. Eur J Pharm Sci. 2008;34(2–3):164–72.

    Article  CAS  Google Scholar 

  5. Carabias L, Llaudó J, Ayani I, Martínez-González J, Litman R, Gutierro I. A phase II study to evaluate the pharmacokinetics, safety, and tolerability of risperidone ISM multiple intramuscular injections once every 4 weeks in patients with schizophrenia. Int Clin Psychopharmacol. 2017;33(2):79–877.

    Article  Google Scholar 

  6. Llaudó J, Anta L, Ayani I, et al. Phase I, open-label, randomized, parallel study to evaluate the pharmacokinetics, safety, and tolerability of one intramuscular injection of risperidone ISM at different dose strengths in patients with schizophrenia or schizoaffective disorder (PRISMA-1). Int Clin Psychopharmacol. 2016;31(6):323–31.

    Article  Google Scholar 

  7. ROVI. ROVI announces the commencement of the assessment process to obtain marketing authorisation for Doria® in the European Union. 2020. https://www.rovi.es/sites/default/files/Doria%20validation_Press%20release_0.pdf. Accessed 25 Aug 2020.

  8. Laffont C, Gomeni R, Zheng B, et al. Population pharmacokinetic modeling and simulation to guide dose selection for RBP-7000, a new sustained-release formulation of risperidone. J Clin Pharmacol. 2015;55(1):93–103.

    Article  CAS  Google Scholar 

  9. Samtani MN, Gopal S, Gassmann-Mayer C, Alphs L, Palumbo JM. Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data. CNS Drugs. 2011;25:829–45.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Department, Laboratorios Farmacéuticos ROVI, S.A., Calle Alfonso Gómez, 45A, 28037, Madrid, Spain

    Lourdes Anta

  2. R&D Department, Laboratorios Farmacéuticos ROVI, Granada, Spain

    Elena Mata & Lourdes Ochoa Díaz de Monasterioguren

Authors
  1. Lourdes Anta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elena Mata
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lourdes Ochoa Díaz de Monasterioguren
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lourdes Anta.

Ethics declarations

Funding

No funding was received for the preparation of this letter.

Conflicts of interest/competing interests

Lourdes Anta, Elena Mata, and Lourdes Ochoa Díaz de Monasterioguren are employees of Laboratorios Farmacéuticos ROVI, S.A., the sole developer of Risperidone ISM®.

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and material

Not applicable.

Code Availability

Not applicable.

Authors’ contributions

Not applicable.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Anta, L., Mata, E. & Ochoa Díaz de Monasterioguren, L. Newer Formulations of Risperidone: Remarks About Risperidone ISM®. CNS Drugs 34, 1087–1088 (2020). https://doi.org/10.1007/s40263-020-00762-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-020-00762-0

Search

Navigation